Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at $1.58, down 36 cents, in afternoon trading on March 9.Read More
Can-Fite BioPharma’s (NYSE MKT:CANF; TASE:CFBI) subsidiary, OphthaliX (OTC:OPLI) released top-line results from its Phase 2 clinical trial of CF101 for the treatment of glaucoma.
No statistically significant differences were found between the CF101 treated group and the placebo group in the primary endpoint of lowering intra ocular pressure (IOP). High IOP is a characteristic of glaucoma. CF101 was found to have a favorable safety profile and was well tolerated.Read More
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has reported new findings for its drug candidate, CF602, showing statistically significant full recovery from erectile dysfunction after one single dose treatment in a preclinical diabetic model.
Can-Fite plans to file an IND application with the FDA for CF602 in the fourth quarter this year and plans to initiate a Phase 1 trial following IND approval.Read More
Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent titled, “A3 Adenosine Receptor Allosteric Modulators”.
The composition of matter patent protects the use of Can-Fite’s proprietary A3 Adenosine Receptor (A3AR) modulator, including the preparation of its pharmaceutical compositions and its use in patients across all therapeutic indications.Read More